Financial Review: AIM ImmunoTech (NYSE:AIM) & Monte Rosa Therapeutics (NASDAQ:GLUE)
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) and AIM ImmunoTech (NYSE:AIM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, institutional ownership, earnings and dividends. Earnings and Valuation This table compares […]
More Stories
Smartsheet (NYSE:SMAR) Earns Neutral Rating from Citigroup
Citigroup reissued their neutral rating on shares of Smartsheet (NYSE:SMAR – Free Report) in a research note issued to investors...
Camping World (NYSE:CWH) PT Raised to $30.00
Camping World (NYSE:CWH – Free Report) had its price objective increased by Monness Crespi & Hardt from $24.00 to $30.00...
Oppenheimer Boosts DoorDash (NASDAQ:DASH) Price Target to $160.00
DoorDash (NASDAQ:DASH – Free Report) had its price target boosted by Oppenheimer from $145.00 to $160.00 in a research note...
Reviewing ASICS (OTCMKTS:ASCCF) and adidas (OTCMKTS:ADDYY)
ASICS (OTCMKTS:ASCCF – Get Free Report) and adidas (OTCMKTS:ADDYY – Get Free Report) are both consumer cyclical companies, but which...
Comparing Lithia Motors (NYSE:LAD) and AutoCanada (OTCMKTS:AOCIF)
AutoCanada (OTCMKTS:AOCIF – Get Free Report) and Lithia Motors (NYSE:LAD – Get Free Report) are both consumer cyclical companies, but...
INmune Bio (NASDAQ:INMB) Earns Outperform Rating from Analysts at Raymond James
Raymond James assumed coverage on shares of INmune Bio (NASDAQ:INMB – Free Report) in a research report released on Friday...